Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury

Brain

Volumn 135, Issue 4, 2012, Pages 1224-1236

  Casha, Steven ^a   Zygun, David ^a   McGowan, M Dan ^a   Bains, Ish ^a   Yong, V Wee ^a   John Hurlbert, R ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

human; minocycline; randomized control trial; spinal cord injury

Indexed keywords

MINOCYCLINE; PLACEBO;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; CEREBROSPINAL FLUID; CERVICAL SPINE INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INJURY SEVERITY; LOADING DRUG DOSE; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SPINAL CORD INJURY; STEADY STATE; THORAX INJURY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84860146607     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws072     Document Type: Article

References (32)

1. Carney S, Butcher RA, Dawborn JK, Pattison G. Minocycline excretion and distribution in relation to renal function in man. Clin Exp Pharmacol Physiol 1974; 1: 299-308.
2. Cunliffe WJ. Minocycline for acne. Doctors should not change the way they prescribe for acne. BMJ 1996; 312: 1101.
3. DTB. Is minocycline overused in acne? Drug and Therapeutics Bulletin 2006; 44: 60-4.
4. Fagan SC, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark WM, et al. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke 2010; 41: 2283-7.
5. Fawcett JW, Curt A, Steeves JD, Coleman WP, Tuszynski MH, Lammertse D, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007; 45: 190-205. (Pubitemid 46340848)
6. Festoff BW, Ameenuddin S, Arnold PM, Wong A, Santacruz KS, Citron BA. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 2006; 97: 1314-26. (Pubitemid 43725571)
7. Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004; 62: 1845-7. (Pubitemid 38661748)
8. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045-53. (Pubitemid 350116691)
9. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996; 312: 169-72. (Pubitemid 26026289)
10. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996; 134: 693-5. (Pubitemid 26120737)
11. Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology 2004; 63: 547-9.
12. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69: 1404-10. (Pubitemid 47511461)
13. Lee JH, Tigchelaar S, Liu J, Stammers AM, Streijger F, Tetzlaff W, et al. Lack of neuroprotective effects of simvastatin and minocycline in a model of cervical spinal cord injury. Exp Neurol 2010; 225: 219-30.
14. Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 2003; 20: 1017-27. (Pubitemid 37288561)
15. Macdonald H, Kelly RG, Allen ES, Noble JF, Kanegis LA. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 1973; 14: 852-61.
16. Matsukawa N, Yasuhara T, Hara K, Xu L, Maki M, Yu G, et al. Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci 2009; 10: 126.
17. Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2004; 55: 756. (Pubitemid 38544341)
18. Newman TB. If almost nothing goes wrong, is almost everything all right? Interpreting small numerators. JAMA 1995; 274: 1013.
19. NINDS NET-PD Investigators. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 2008; 31: 141-50.
20. Pinzon A, Marcillo A, Quintana A, Stamler S, Bunge MB, Bramlett HM, et al. A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. Brain Res 2008; 1243: 146-51.
21. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol 2010; 67: 1442-8.
22. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002; 51: 215-23. (Pubitemid 34111444)
23. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997; 133: 1224-30. (Pubitemid 27443814)
24. Shepard MJ, Bracken MB. The effect of methylprednisolone, naloxone, and spinal cord trauma on four liver enzymes: observations from NASCIS 2. National Acute Spinal Cord Injury Study. Paraplegia 1994; 32: 236-45. (Pubitemid 24166942)
25. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004; 24: 2182-90. (Pubitemid 38314550)
26. Tator CH. Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery 2006; 59: 957-82. (Pubitemid 44852056)
27. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA 2004; 101: 3071-6. (Pubitemid 38327736)
28. Wells JE, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003; 126: 1628-37. (Pubitemid 36834939)
29. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004; 3: 744-51. (Pubitemid 39535260)
30. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998; 95: 15769-74. (Pubitemid 29018775)
31. Yune TY, Lee JY, Jung GY, Kim SJ, Jiang MH, Kim YC, et al. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci 2007; 27: 7751-61. (Pubitemid 47093808)
32. Zhang Y, Metz LM, Yong VW, Bell RB, Yeung M, Patry DG, et al. Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci 2008; 35: 185-91. (Pubitemid 351831055)